Cancer immunotherapy targeting the telomerase reverse transcriptase

Long Fei Huo; Janice Ws Tang; Jun Jian Huang; Pei Tang Huang; Cui Fen Huang; Hsiang Fu Kung; Marie C Lin

Cancer immunotherapy targeting the telomerase reverse transcriptase

Cell Mol Immunol. 2006 Feb;3(1):1-11.

Authors

Long Fei Huo¹, Janice Ws Tang, Jun Jian Huang, Pei Tang Huang, Cui Fen Huang, Hsiang Fu Kung, Marie C Lin

Affiliation

¹ Open Laboratory of Chemical Biology of the Institute of Molecular Technology, Department of Chemistry, The University of Hong Kong, Pokfulam, China.

PMID: 16549043

Abstract

The human telomerase reverse transcriptase (hTERT) is expressed in more than 85% of tumor cells but is usually not found in normal cells, which makes hTERT as an ideal tumor-associate antigen (TAA) to develop potential vaccine specifically destroying cancers without impairing normal tissues in human cancer immunotherapy. Here are reviewed the fundamental advances of studies on immunogenicity of hTERT or its peptides and the early clinical trials using the hTERT vaccine approach in the last decades.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antigens, Neoplasm / immunology*
Antigens, Neoplasm / metabolism
Cancer Vaccines / immunology*
Cancer Vaccines / therapeutic use
Clinical Trials as Topic
DNA-Binding Proteins / immunology*
DNA-Binding Proteins / metabolism
Humans
Immunotherapy*
Neoplasms / immunology
Neoplasms / therapy*
Peptides / immunology*
Peptides / therapeutic use
Telomerase / immunology*
Telomerase / metabolism

Substances

Antigens, Neoplasm
Cancer Vaccines
DNA-Binding Proteins
Peptides
Telomerase